The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
基本信息
- 批准号:9404820
- 负责人:
- 金额:$ 77.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS related cancerAIDS/HIV problemAcquired Immunodeficiency SyndromeAcute DiseaseAddressAffectAfricaAfrica South of the SaharaAnti-Retroviral AgentsAreaBiometryCancer BiologyCancer BurdenCancer DiagnosticsCancer Research InfrastructureCancer Research ProjectCervical dysplasiaChronicClinical TreatmentCollaborationsCore FacilityCountryCoupledDeveloping CountriesDiagnosisDiseaseEducational workshopEpidemicEpidemiologyEye NeoplasmsFemaleFundingGoalsHIVHIV-1HealthHealthcare SystemsHospitalsHuman ResourcesImmunosuppressionIncidenceIndividualInstitutionInterdisciplinary StudyInternational AIDSInvestmentsKaposi SarcomaLeadLeadershipMalignant NeoplasmsMedical centerMentorsMolecularNational Cancer InstituteNebraskaNeoplasmsOutcomePathogenesisPathologyPhysiciansPilot ProjectsPrevalencePreventionResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResearch TrainingScientistScreening for cancerTeaching HospitalsTechnology TransferTimeTrainingTraining ActivityTraining ProgramsTraining and InfrastructureUnited StatesUniversitiesViralWorkZambiaanticancer researchcancer carecancer genomicsclinical careimprovedmaleneglectnext generationocular surfaceoncologypotential biomarkerprogramssuccessvirology
项目摘要
ABSTRACT
The establishment of the Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP) will
support the U.S.-Zambia collaborations necessary to develop a robust cancer research infrastructure at
Zambia’s Cancer Diseases Hospital (CDH) and University Teaching Hospital (UTH), with an initial focus on
Kaposi’s sarcoma (KS) and ocular surface squamous neoplasia (OSSN) – two of the most common occurring
HIV/AIDS-associated malignancies in the country. ZAMDAPP will, for the first time, provide a mechanism by
which R01-style research projects led by Zambian scientists trained through the Fogarty International AIDS
International Research and Training Program (AITRP, D43TW001429) and AIDS Malignancies Training and
Research Program (AMTRP, D43TW010354) may be conducted in three areas critical to cancer research –
virology, biostatistics and epidemiology, and cancer diagnostics. The Zambian personnel leading the research
projects will benefit from mentoring by U.S. partners and support by a number of research core facilities.
ZAMDAPP will leverage strengths in clinical care and treatment at CDH and UTH; strengths in molecular viral
oncology research and cancer genomics at the University of Nebraska-Lincoln; and strengths in pathology,
epidemiology, and biostatistics at the University of Nebraska Medical Center, while extending the work that has
been accomplished through AITRP and AMTRP, which provide support for trainees to pursue advanced
degrees. In addition to providing research funding, ZAMDAPP will provide diverse training activities in the
United States and Zambia to engage the next generation of Zambian cancer researchers, increase local
expertise, and enhance the transfer of technology. The partnership will lead to exchanges that build the
technical and personnel infrastructure necessary to perform the high-quality and sustainable cancer research
desperately needed in Zambia. Three specific aims will be accomplished: 1) develop the cancer research
infrastructure at UTH and CDH through the establishment and enhancement two research core facilities; 2)
provide an opportunity for former Fogarty trained fellows to lead hypothesis-driven research projects in the two
more prevalent AIDS-associated malignancies, KS and OSSN, with the support of the U.S. partners and the
core facilities; and 3) develop a pipeline of next generation Zambian cancer researchers through a) in-country
workshops, b) pilot project funding, and c) short-term U.S. technical training. ZAMDAPP will build on
successful ongoing Fogarty and National Cancer Institute training programs led by the PI and the leadership
team in sub-Saharan Africa; implement a cross-disciplinary research and training program with different
training tracks and in-country research projects that pair Zambian and U.S. researchers along with
opportunities to conduct hypothesis-driven research projects; and be Zambian driven and benefit from broad
local support. Thus, there is strong potential for ZAMDAPP to success in reaching its goal.
抽象的
赞比亚艾滋病恶性肿瘤诊断和发病机制项目(ZAMDAPP)的建立将
支持美国与赞比亚之间的合作,以开发强大的癌症研究基础设施
赞比亚癌症疾病医院 (CDH) 和大学教学医院 (UTH),最初的重点是
卡波西肉瘤 (KS) 和眼表鳞状细胞瘤 (OSSN) – 两种最常见的肿瘤
ZAMDAPP 将首次在该国提供一种与艾滋病毒/艾滋病相关的恶性肿瘤的机制。
由赞比亚科学家领导的R01型研究项目通过福格蒂国际艾滋病培训
国际研究和培训计划(AITRP,D43TW001429)和艾滋病恶性肿瘤培训和
研究计划(AMTRP,D43TW010354)可在对癌症研究至关重要的三个领域进行 -
病毒学、生物统计学和流行病学以及癌症诊断领域的赞比亚人员领导了这项研究。
项目将受益于美国合作伙伴的指导和许多研究核心设施的支持。
ZAMDAPP 将利用 CDH 的临床护理和治疗优势以及 UTH 的分子病毒优势;
内布拉斯加大学林肯分校的肿瘤学研究和癌症基因组学以及病理学优势;
内布拉斯加大学医学中心的流行病学和生物统计学,同时扩展了已经开展的工作
已通过 AITRP 和 AMTRP 完成,为学员追求高级课程提供支持
除了提供研究经费外,ZAMDAPP 还将提供多样化的培训活动。
美国和赞比亚将吸引下一代赞比亚癌症研究人员,增加当地
专业知识,并加强技术转让,这种伙伴关系将促进建立互利共赢的交流。
进行高质量和可持续的癌症研究所需的技术和人员基础设施
将实现赞比亚迫切需要的三个具体目标:1)发展癌症研究。
通过建立和加强两个研究核心设施,UTH 和 CDH 的基础设施2);
为前福格蒂培训研究员提供机会,领导这两个领域的假设驱动研究项目
在美国合作伙伴和
核心设施;3) 通过 a) 国内开发下一代赞比亚癌症研究人员的渠道
研讨会、b) 试点项目资金和 c) 短期美国技术培训将以此为基础。
由 PI 和领导层领导的正在进行的 Fogarty 和国家癌症研究所培训计划取得成功
撒哈拉以南非洲团队实施跨学科研究和培训计划
赞比亚和美国研究人员结对的培训课程和国内研究项目
进行假设驱动的研究项目的机会;并受到赞比亚的驱动并从广泛的利益中受益
因此,ZAMDAPP 成功实现其目标的潜力很大。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chipepo Kankasa其他文献
Chipepo Kankasa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chipepo Kankasa', 18)}}的其他基金
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10542913 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10618999 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10405562 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement
赞比亚艾滋病恶性肿瘤诊断和发病机制计划补充资料
- 批准号:
10381368 - 财政年份:2017
- 资助金额:
$ 77.03万 - 项目类别:
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
- 批准号:
10242673 - 财政年份:2017
- 资助金额:
$ 77.03万 - 项目类别:
相似海外基金
Tanzania AIDS Malignancies Training and Research International Program (TAMTRP)
坦桑尼亚艾滋病恶性肿瘤培训和研究国际计划 (TAMTRP)
- 批准号:
10650673 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10405562 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)
应激角蛋白 17 和 CD4/8 比率作为 HIV 相关肛门生殖器鳞状细胞癌前病变和癌症的预后标志物 (Biospecimens/Biocohort)
- 批准号:
10620051 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
Defining the genomic and microenvironmental features of diffuse large B cell lymphoma in HIV + patients (Biospecimens/Biocohort)
定义 HIV 患者弥漫性大 B 细胞淋巴瘤的基因组和微环境特征(生物样本/生物队列)
- 批准号:
10619709 - 财政年份:2022
- 资助金额:
$ 77.03万 - 项目类别:
Molecular mechanisms governing the ubiquitination signaling during KSHV cell entry and tumorigenesis
KSHV 细胞进入和肿瘤发生过程中泛素化信号传导的分子机制
- 批准号:
10434156 - 财政年份:2021
- 资助金额:
$ 77.03万 - 项目类别: